Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | PDE5A | O76074 | 10/20 | 0.53 |
| ▸ | BUB1 | O43683 | 4/20 | 0.47 |
| ▸ | GUCY1A1 | Q02108 | 4/20 | 0.46 |
| ▸ | GUCY1B1 | Q02153 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14282081 | 0.92 | ADORA3 (0.59) | ADORA3KCNH2PDE5ABUB1GUCY1A1 | |
| SCHEMBL14282089 | 0.90 | ADORA3 (0.57) | ADORA3KCNH2PDE5ABUB1GUCY1A1 | |
| SCHEMBL14282080 | 0.90 | ADORA3 (0.60) | ADORA3KCNH2PDE5ABUB1GUCY1A1 | |
| SCHEMBL14282088 | 0.89 | ADORA3 (0.55) | ADORA3KCNH2PDE5ABUB1GUCY1A1 | |
| SCHEMBL14282090 | 0.88 | ADORA3 (0.56) | ADORA3KCNH2PDE5ABUB1GUCY1A1 | |
| SCHEMBL14282086 | 0.88 | ADORA3 (0.54) | ADORA3KCNH2PDE5ABUB1GUCY1A1 | |
| SCHEMBL14282083 | 0.87 | ADORA3 (0.57) | ADORA3KCNH2PDE5ABUB1GUCY1A1 | |
| SCHEMBL14282085 | 0.87 | PDE5A (0.52) | ADORA3KCNH2PDE5ABUB1GUCY1A1 | |
| SCHEMBL14282082 | 0.87 | ADORA3 (0.55) | ADORA3KCNH2PDE5ABUB1GUCY1A1 | |
| SCHEMBL4939648 | 0.87 | ADORA3 (0.64) | ADORA3KCNH2PDE5ABUB1GUCY1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7317016-B2 | Methods of treating medical conditions using sulfonate-substituted pyrazolopyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2008-01-08 | — | — | US | disclosed |
| US-7317016-B2 | Methods of treating medical conditions using sulfonate-substituted pyrazolopyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2008-01-08 | — | — | US | disclosed |
| US-7317016-B2 | Methods of treating medical conditions using sulfonate-substituted pyrazolopyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2008-01-08 | — | — | US | disclosed |
| US-20050245553-A1 | Methods of treating medical conditions using sulfonate-substituted pyrazolopyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-11-03 | — | — | US | disclosed |
| US-6919345-B2 | Sulfonate substituted pyrazol pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-07-19 | — | — | US | disclosed |
| US-20040171832-A1 | Novel sulfonate substituted pyrazol pyridine derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245553-A1 | Methods of treating medical conditions using sulfonate-substituted pyrazolopyridine derivatives | PTGER3, TBXA2R, STS | ADORA3 444/4885KCNH2 346/4885PDE5A 1429/4885 |
| US-20040171832-A1 | Novel sulfonate substituted pyrazol pyridine derivatives | NOS3, PDE3A, GPR3 | ADORA3 112/4885KCNH2 605/4885PDE5A 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.